Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1981 1
1983 1
1984 3
1985 4
1986 2
1987 3
1988 8
1989 5
1990 9
1991 12
1992 9
1993 17
1994 23
1995 19
1996 32
1997 34
1998 29
1999 29
2000 50
2001 43
2002 64
2003 78
2004 105
2005 115
2006 105
2007 161
2008 167
2009 199
2010 242
2011 294
2012 349
2013 337
2014 413
2015 487
2016 548
2017 582
2018 711
2019 838
2020 1011
2021 1159
2022 1432
2023 1313
2024 478

Text availability

Article attribute

Article type

Publication date

Search Results

10,246 results

Results by year

Filters applied: . Clear all
Page 1
Osteocyte mitochondria inhibit tumor development via STING-dependent antitumor immunity.
Zhou H, Zhang W, Li H, Xu F, Yinwang E, Xue Y, Chen T, Wang S, Wang Z, Sun H, Wang F, Mou H, Yao M, Chai X, Zhang J, Diarra MD, Li B, Zhang C, Gao J, Ye Z. Zhou H, et al. Among authors: xue y. Sci Adv. 2024 Jan 19;10(3):eadi4298. doi: 10.1126/sciadv.adi4298. Epub 2024 Jan 17. Sci Adv. 2024. PMID: 38232158 Free PMC article.
Self-Healing Hydrogel Bioelectronics.
Li Z, Lu J, Ji T, Xue Y, Zhao L, Zhao K, Jia B, Wang B, Wang J, Zhang S, Jiang Z. Li Z, et al. Among authors: xue y. Adv Mater. 2023 Nov 21:e2306350. doi: 10.1002/adma.202306350. Online ahead of print. Adv Mater. 2023. PMID: 37987498 Review.
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.
Tong X, Patel AS, Kim E, Li H, Chen Y, Li S, Liu S, Dilly J, Kapner KS, Zhang N, Xue Y, Hover L, Mukhopadhyay S, Sherman F, Myndzar K, Sahu P, Gao Y, Li F, Li F, Fang Z, Jin Y, Gao J, Shi M, Sinha S, Chen L, Chen Y, Kheoh T, Yang W, Yanai I, Moreira AL, Velcheti V, Neel BG, Hu L, Christensen JG, Olson P, Gao D, Zhang MQ, Aguirre AJ, Wong KK, Ji H. Tong X, et al. Among authors: xue y. Cancer Cell. 2024 Mar 11;42(3):413-428.e7. doi: 10.1016/j.ccell.2024.01.012. Epub 2024 Feb 22. Cancer Cell. 2024. PMID: 38402609 Free article.
Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1.
Wattenberg MM, Coho H, Herrera VM, Graham K, Stone ML, Xue Y, Chang RB, Cassella C, Liu M, Choi-Bose S, Thomas SK, Choi H, Li Y, Markowitz K, Melendez L, Gianonne M, Bose N, Beatty GL. Wattenberg MM, et al. Among authors: xue y. Sci Immunol. 2023 Nov 17;8(89):eadj5097. doi: 10.1126/sciimmunol.adj5097. Epub 2023 Nov 17. Sci Immunol. 2023. PMID: 37976347
Targeting the DNA Damage Response for Cancer Therapy.
Wang R, Sun Y, Li C, Xue Y, Ba X. Wang R, et al. Among authors: xue y. Int J Mol Sci. 2023 Nov 2;24(21):15907. doi: 10.3390/ijms242115907. Int J Mol Sci. 2023. PMID: 37958890 Free PMC article. Review.
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation.
Qin Z, Yue M, Tang S, Wu F, Sun H, Li Y, Zhang Y, Izumi H, Huang H, Wang W, Xue Y, Tong X, Mori S, Taki T, Goto K, Jin Y, Li F, Li FM, Gao Y, Fang Z, Fang Y, Hu L, Yan X, Xu G, Chen H, Kobayashi SS, Ventura A, Wong KK, Zhu X, Chen L, Ren S, Chen LN, Ji H. Qin Z, et al. Among authors: xue y. J Exp Med. 2024 Mar 4;221(3):e20232028. doi: 10.1084/jem.20232028. Epub 2024 Jan 29. J Exp Med. 2024. PMID: 38284990
10,246 results
You have reached the last available page of results. Please see the User Guide for more information.